Bright Minds Biosciences Inc. DRUG R2K
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DRUG Bright Minds Biosciences Inc. R2K | 88.07 | - | $864.15M | - | -16.98% | -15.02% | - | 6.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.35M | 3.30M | 5.66M | 6.90M | 15.32M |
| Operating Income | - | -3.35M | -3.30M | -5.66M | -6.90M | -15.32M |
| EBITDA | - | -3.33M | -3.28M | -5.65M | -6.88M | -15.30M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -2.95M | -5.24M | -4.09M | -7.57M | -10.46M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -2.95M | -5.24M | -4.09M | -7.57M | -10.46M |
| Diluted EPS | 0.01 | -0.42 | -0.74 | - | -0.97 | -1.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 14.98M | 7.39M | 2.82M | 13.94M |
| Operating Income | - | -14.98M | -7.39M | -2.82M | -13.94M |
| EBITDA | - | -14.97M | -7.31M | -2.75M | -13.86M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -14.96M | -7.37M | -2.80M | -12.23M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -14.96M | -7.37M | -2.80M | -12.23M |
| Diluted EPS | - | -6.06 | -1.98 | -0.65 | -1.78 |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 6.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +239.38% |
| 6 Months: | +34.40% |
| 3 Months: | +5.07% |
| 1 Month: | -1.17% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.09M | 6.88M | 6.10M | 84.42M |
| Current Assets | - | 11.95M | 6.81M | 5.99M | 84.31M |
| Cash & Equivalents | - | 11.63M | 6.75M | 5.72M | 82.91M |
| Inventory | - | - | - | - | - |
| Receivables | - | 155.78K | 36.98K | 50.22K | 413.07K |
| Total Liabilities | - | 1.54M | 280.86K | 568.26K | 2.38M |
| Current Liabilities | - | 1.47M | 280.86K | 528.68K | 2.34M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 139.91K | 73.55K | 118.96K | 125.78K |
| Total Equity | - | 10.54M | 6.60M | 5.54M | 82.04M |
| Shares Outstanding | - | 3.52M | 3.77M | 4.52M | 7.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -13.59M | -7.02M | -1.85M | -8.69M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | 5.20M | 2.19M | 810.57K | 85.57M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -13.59M | -7.02M | -1.85M | -8.69M |
| Net Change in Cash | - | -8.39M | -4.83M | -1.04M | 76.88M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -141.9% | -111.7% | -50.6% | -14.9% |
| ROCE % | - | -141.1% | -111.9% | -50.6% | -17.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 13.20% | 1.28M | $113.11M |
| 2 | Cormorant Asset Management, LP | 10.88% | 1.06M | $93.30M |
| 3 | Blackrock Inc. | 6.39% | 621.93K | $54.77M |
| 4 | Vivo Capital, LLC | 5.73% | 557.17K | $49.07M |
| 5 | Braidwell LP | 5.55% | 539.71K | $47.53M |
| 6 | Adage Capital Partners GP L.L.C. | 5.09% | 495.74K | $43.66M |
| 7 | Vestal Point Capital, LP | 5.06% | 492.32K | $43.36M |
| 8 | Driehaus Capital Management, LLC | 4.44% | 432.51K | $38.09M |
| 9 | Perceptive Advisors Llc | 3.88% | 377.54K | $33.25M |
| 10 | Balyasny Asset Management LP | 3.05% | 297.16K | $26.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DRUG
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.